---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-058223"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:39:50.444380+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# TELA Bio Q1 revenue $8.2M (+40% YoY); net loss widens to $10.9M

## Summary
- Revenue grew 40% YoY to $8.2M; OviTex PRS revenue up 111% YoY.
- Gross margin improved to 61% from 59% on lower excess/obsolete inventory adjustments.
- Net loss $10.9M vs $8.1M; operating loss $9.8M vs $7.3M.
- Cash and equivalents $33.0M; FY2022 revenue guidance reaffirmed at $40-45M.
- Appointed D. Taylor Ocasio as General Counsel.

## SEC filing metadata
- accession: 0001104659-22-058223
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465922058223/0001104659-22-058223-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465922058223/tm2215020d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-058223
- JSON: https://secwatch.observer/filing/0001104659-22-058223.json
- Plain text: https://secwatch.observer/filing/0001104659-22-058223.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.